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ABSTRACT 
 
Cancer immunotherapy refers to the stimulation of the immune system to eliminate cancer 
cells and can be applied by several different means. One form of cancer immunotherapy is 
therapeutic vaccination with the goal to generate de novo, and boost existing tumor antigen 
specific T cells. A crucial step in the development of a cancer vaccine is antigen selection. 
Ideally, an antigen should be uniquely expressed by tumor cells with low or no expression in 
healthy tissue. Also, the antigen should also be immunogenic and expressed on the cell 
surface, to be targetable both by cellular and humoral immunity. Cripto-1 (Cr-1) is a 
membrane bound oncofetal glycoprotein expressed in human cancer. Furthermore, Cr-1 is 
involved in epithelial-mesenchymal transition and found to be expressed by cancer stem cells 
(CSC). Thus, Cr-1 could represent a potential candidate for cancer immunotherapy. 
Circulating Cr-1 has also been found at elevated levels in patients with cancer and has been 
proposed as a biomarker in patients with non-small cell lung cancer. However, T cell 
reactivity against Cr-1 has not yet been reported in humans. We studied if vaccination against 
Cr-1 would result in protective anti-tumor immunity in models of melanoma and breast 
cancer. Furthermore, we explored the potential of soluble Cr-1 as a prognostic biomarker for 
patients with advanced melanoma and evaluated peripheral T cell reactivity to Cr-1 in these 
patients.  
We found that Cr-1 DNA vaccination elicits a Cr-1 specific cellular and humoral immune 
response in C57Bl/6 and BALB/c mice respectively. The induced Cr-1 directed immune 
response was protective in murine melanoma and mammary carcinoma models. Prophylactic 
vaccination particularly reduced metastatic burden and partially prevented tumor formation 
from CSC. In patients with advanced melanoma we showed that low serum levels of soluble 
Cr-1 after surgery correlated with longer survival. Additionally, we detected Cr-1 reactive T 
cells in peripheral blood of patients with advanced melanoma and the presence of Cr-1 
reactive T cells before surgery correlated with improved survival.  
In summary, vaccination against Cr-1 elicits antigen-specific protective immune responses 
against melanoma and breast cancer. Furthermore, soluble Cr-1 protein and T cell reactivity 
against Cr-1 can serve as biomarkers in patients with advanced melanoma. Altogether, our 
observations demonstrate that Cr-1 is a potential target for cancer immunotherapy.  
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1 INTRODUCTION 
 
1.1 CANCER 
The term cancer describes a heterogeneous group of diseases. Cancers are characterized by 
uncontrolled growth, cell division, and the ability to disseminate to distant locations. What all 
cancers have in common are characteristics required for cell transformation and malignant 
progressions. In 2000, Hanahan and Weinberg proposed six hallmarks of cancer shared 
among all tumor types: 1) sustained proliferation, 2) evading growth suppressors, 3) 
replicative immortality, 4) induction of angiogenesis, 5) resisting cell death, and 6) activation 
of invasion and metastasis. (1) It is essential for tumors to acquire all 6 traits in order to 
progress, however it appears to be irrelevant, in which order they occur. (1) 
It is generally accepted that tumor development is a multistep process of genetic and 
epigenetic alterations through which normal cells turn into malignant cell formations called 
cancer. Somatic mutations occur frequently in cells and accumulate over time. A small 
number of genes have been identified as oncogenes, which are often found mutated in cancer. 
(2, 3) Oncogenes are able to promote cell transformation through disabling or evading 
stringent intrinsic cellular control pathways for proliferation and division. Throughout 
tumorigenesis, cancer cells undergo a positive selective pressure for cell clones with 
beneficial mutations for survival and proliferation. (4, 5)   
 
Figure 1: Hallmarks of cancer (adapted from Hanahan and Weinberg, 2011) (6) 
 
The traditional six hallmarks reflect the one-sided view researchers have had on cancer for 
decades. While cancer research has primarily been focused on just the tumor cells 
themselves, it has become apparent there is a crosstalk between tumor cells, tissue stroma and 
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immune cells. The introduction of 4 additional hallmarks is the result of research seeing 
cancer as a complex and heterogeneous cell system. (6)  The addition of the two hallmarks 
‘tumor promoting inflammation’ and ‘avoiding immune destruction’ acknowledge the 
significance of the close crosstalk between tumor cells and the immune system (Figure 1). (6)  
 
1.1.1 Epithelial-mesenchymal transition 
Metastases are the most life-threatening for all cancer patients. Although immunotherapy has 
prolonged overall survival (OS) for patients with metastatic disease, long time responses are 
only observed in a very small fraction of patients.  (7-9) 
There is extensive evidence that epithelial-mesenchymal transition (EMT) plays a major role 
in the metastatic process. (10, 11) The expression of EMT associated proteins in cancer has 
been linked to tumor progression. (10, 12, 13) EMT is a fundamental cellular process during 
embryogenesis and highly conserved among different species. (14) It is defined by 
phenotypical and molecular changes including loss of cell adhesion, decreased proliferation 
and increased cell motility. (10, 15, 16) Snail, Twist and ZEB are key transcription factors in 
the EMT signaling network. (10) EMT can be initiated by various mechanisms including 
TGFβ, TNFα, and hypoxia. (17-20) Loss of e-cadherin, through nuclear re-localization of β-
catenin, activates the expression of Snail and transcription factors related to proliferation, 
migration and invasion. (21, 22) Wnt signaling enhances EMT by preventing the degradation 
of β-catenin in the nucleus. (23) Decreased cell adhesion, through loss of e-cadherin, was 
found to promote metastasis. (24) After migration of tumor cells from the primary tumor, 
mesenchymal-epithelial transition is required to establish metastatic colonies. (25) 
Tumor cells that undergo EMT have been shown to escape immune recognition through 
various mechanisms, including cytoskeletal changes, expression of PD-L1, and changes in 
antigen repertoire, among others. (26-28) 
1.1.2 Cancer stem cells 
Cancer stem cells (CSCs) are subpopulation of cancer cells with characteristics similar to 
normal stem cells. (29, 30) They have self-renewal capacity and tumor initiating potential. 
(29, 30) CSCs have been identified and isolated from a range of solid tumors including 
breast, colon and pancreatic cancer. (31-36) Known stem cell markers ALDH, CD133 and 
CD44, are used to identify CSC within tumors. (37) In epithelial tumors, dedifferentiation of 
tumor cells through genetic or epigenetic alterations can give rise to CSCs. (30, 38) There is 
evidence for a tight link between EMT and stem cell phenotype in cancer. (39, 40) The EMT 
process can induce a CSC phenotype through shared pathways like notch, Wnt, and 
hedgehog, which control stem cell renewal and maintenance in normal stem cells. (41-43) 
CD44 is a target of β-catenin. Induction of EMT in breast cancer cells resulted in expression 
of CSCs markers. (44, 45) Because CSCs often have an EMT phenotype, they have been 
proposed as a source for metastasis. (46) 
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CSCs are involved in tumor progression and are resistant to chemotherapy and radiotherapy. 
(47-51) Several mechanisms have been identified that are the basis for the increased 
therapeutic resistance compared to non-stem cell like tumor cells. (52-55) Due to treatment 
resistance and intrinsic tumorigenicity, CSCs are a potential cause for relapse. (56)  
 
1.1.3 Melanoma 
Melanoma is a malignant transformation of melanocytes and the most aggressive skin cancer. 
The most common form is cutaneous melanoma that arises from the basal layer of the 
epidermis. Exposure to ultraviolet radiation is the main risk factor to develop melanoma, 
especially exposure at young age. (57, 58) The incidence rates of melanoma have been rising 
strongly in recent years. (59, 60) Cutaneous melanoma has a high mutational burden. (61) 
The most common recurrent mutations are in the proto-oncogenes BRAF and NRAS, and the 
tumor suppressor genes CDKN2A and PTEN. (62) The classic melanoma staging is based on 
the adverse prognostic factors of Clark’s level of invasion and Breslow’s tumor thickness, 
complemented with ulceration status and mitotic rate. (63-66) The 5-year OS rates, before the 
introduction of targeted therapies, range from 91% at stage I, through 62% and 57% at stage 
II and III to only 25% at stage IV. (67) The primary treatment option for melanoma is 
surgery. For metastatic melanoma, treatment with BRAF-inhibitors, anti-CTLA-4-antibodies, 
MEK-inhibitors or anti-PD-1-antibodies is indicated. 
 
1.1.4 Breast cancer 
A quarter of all cancer diagnoses in women are breast cancer, which makes it the most 
common malignancy of this sex worldwide. (68) It develops most commonly (95%) in the 
ductal and lobular tissue of the breast. The primary treatment strategy is surgery, but neo-
adjuvant and adjuvant chemo- and radiotherapy is needed in more advanced disease. The 
intrinsic molecular patterns, based on gene expression analysis, subdivide breast cancers into 
4 subtypes. The ‘luminal A’ subtype is estrogen receptor (ER) and/or progesterone receptor 
(PR) positive and human Epidermal growth factor Receptor 2 (HER2) negative, and usually 
only requires endocrine treatment. The ‘luminal B’, ‘HER2-enriched’ and ‘triple-negative’ 
(negative for ER, PR and HER2) subtypes require chemotherapy and endocrine therapy 
(depending on receptor expression) and trastuzumab treatment (depending on HER2 
expression). (69) Together with the size and grade of the tumor, lymph node status and 
distant metastasis, these parameters are used to determine prognosis and optimal treatment. 
(70) The prognosis for ‘triple-negative’ subtype is particularly bad, most likely due to the 
lack of targeted therapy and instead higher tendency to metastasize. (71, 72) The 3-year OS 
by stage at the time of diagnosis is 99% for stage I, 94% for stage II, 76% for stage III and 
42% for stage IV disease. (73) 
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1.2 TUMOR IMMUNOLOGY 
 
1.2.1 Immunosurveillance 
The concept of tumor surveillance by the immune system is not new. Already in 1909, Paul 
Ehrlich hypothesized that the immune system recognizes and eliminates neoplastic cells, 
preventing tumor formation. (74) The first experimental evidence for immune surveillance of 
tumor growth was obtained from serial transplantation experiments in inbred mice with 
methylcholanthrene induced tumors. Inoculated tumor regressed in a fraction of mice and 
tumor development was prevented following subsequent inoculations. (75, 76)  Later studies 
proposed that the presence of tumor specific antigens is involved in tumor rejection and the 
term immunosurveillance was introduced. (77-80) A great number of murine studies, 
reviewed by Dunn et al., show that both innate and adaptive immunity are involved in tumor 
control. (81)  
In addition to these findings in animal studies, evidence for immune surveillance in humans 
was collected. In retrospective studies, patients on systemic immune suppression were found 
to have increased incidence rates of non-viral induced cancer. (82-86)  Presence of tumor 
infiltrating T cells and NK cells positively correlates with good prognosis in various types of 
cancer. (87-95) In parallel, tumor reactive T cells and antibodies were identified. (96-98) It 
has become evident that the immune system closely interacts with tumors throughout various 
stages of tumor progression. Dunn et al. redefined this interaction as immune editing and 
implemented the 3 E’s of immunoediting: Elimination, Equilibrium, and Escape, defining 
three distinct phases. The immunological features of the three phases are shortly presented 
below and have been discussed by Dunn et al. and updated by Mittal et al. (Figure 2). (81, 99, 
100)  
Elimination  
The elimination phase stands at the beginning of tumorigenesis. During cell transformation, 
danger signals are expressed on the cell surface, activating the innate immune response. This 
immune activation is further enhanced through secretion of IFNγ and IL-2 resulting in 
production of chemokines and recruitment of other immune cells. Tumor cells are killed by 
innate immune cells and tumor associated antigens (TAAs) are released. The TAAs can then 
be phagocytized and presented by locally activated DCs. Tumor specific T cells can then be 
activated by DCs in the draining lymph node and migrate to the tumor. Activated T cells 
eliminate tumor cells and enhance the tumor directed immune response through secretion of 
pro-inflammatory cytokines. If elimination of tumor cells is unsuccessful, progression to 
equilibrium will slowly occur. (81, 100)  
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Figure 2: The three E’s of cancer immunoediting (adapted from Dunn et al., 2004) (81) 
 
Equilibrium 
Through mutagenesis, tumor cells can acquire features increasing their resistance to 
elimination by the immune system. Even though transformed cells are still eliminated by the 
innate and adaptive immune response, it is no longer possible to eradicate them completely. 
This balance of proliferation and division on one side, and elimination on the other side is 
called equilibrium. While this phase can last for a long period of time, the tumor cells are 
under constant selective pressure by the local immune response. Immunogenicity will 
gradually decrease and immune suppressive mechanisms will slowly increase, ultimately 
leading to escape of the tumor. (81, 100) 
Escape 
This final phase is reached when tumor cells are no longer recognized by the immune system 
due to various mechanisms, including resistance to apoptosis, down regulation of MHC class 
I, and defects in antigen processing among others. It is known that tumors in this phase 
actively interfere with the immune response through secretion of anti-inflammatory cytokines 
and promotion of immune regulatory cells. (81, 100) 
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1.2.2 Cancer immunotherapy 
Cancer immunotherapy is the stimulation of the immune system to eliminate cancer cells. 
This can be achieved through a number of different strategies, activating, modulating and 
enhancing the cancer patient’s immune system. Here we will discuss three approaches in 
depth: cytokines, adoptive cell therapy and immune checkpoint blockade.  
Cytokines 
Recombinant cytokines were among the first immunotherapeutic agents tested in patients 
with advanced solid tumors. Efficacy of type I interferons was evaluated both in 
hematological and solid tumors. (101) Even though responses in patients with solid tumors 
were limited, IFNα was approved for melanoma.  
IL-2 has been identified as a T cell growth factor and enabled long term in vitro culture of 
lymphocytes. While only a small fraction of patients with metastatic cancer responded to high 
dose IL-2, responses were long lasting. (102, 103) High dose IL-2 was most effective in 
patients with metastatic melanoma and renal cell carcinoma (RCC) and later FDA approved. 
(102, 103) Cytokine therapies can come with great toxicities to due unspecific stimulation of 
the immune system and therefore limit the overall efficacy. Therefore, IL-2 was later given in 
lower doses in combination with other immune therapies to enhance their efficacy. (104, 105) 
Although ex vivo IL-2 expanded lymphokine activated killer (LAK) cells had anti-tumor 
efficacy in mouse models, adoptive transfer of LAK cells together with high dose IL-2 in 
patients with advanced tumors did not have any synergistic effect. (106-108)  
Adoptive cell therapy 
In 1988, the first report was published on adoptively transferred ex vivo expanded tumor 
infiltrating lymphocytes (TILs) supported by short course of IL-2 in patients with metastatic 
melanoma. (109) In a follow up trial, objective clinical response rates were reported in one 
third of the patients, but these were not long lasting. (110) Combination of adoptive TIL 
transfer with prior lymphodepletion increased response rates and induced durable response. 
(111-113) While adoptive cell therapy (ACT) has been a great success in melanoma 
treatment, it is still in early phases for other solid tumor types. Particularly the culture and 
retrieval of TILs have been bottlenecks for the application of this therapy in other metastatic 
tumors. The efforts in this field have been adequately reviewed by Foppen et al. (114)  
Other therapeutic strategies have been explored to overcome the limitations of TIL therapy. 
Genetic engineering of peripheral blood T cells to recognize tumors is an alternative 
approach.  T cells transduced with T cell receptors (TCRs) recognizing known tumor antigens 
have been tested in clinical trials. Partial clinical responses have been reported but where 
accompanied by severe autoimmune responses and unexpected neurotoxicity. (115-117) An 
additional disadvantage is the MHC restriction of the TCR. Only a subset of patients, with 
matching HLA phenotype, is eligible to receive TCR transduced T cells.  
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Chimeric antigen receptors (CARs) are fusion proteins consisting of intracellular TCR 
signaling components and an extracellular single-chain variable fragment of an antibody. The 
advantage of CAR transduced T cells is that they are not restricted by epitope presentation on 
MHC molecules. However, the fact that target antigens need to be expressed on the cell 
surface is a major hurdle for CAR T cell therapy. CAR T cells against various antigens have 
been tested in clinical trials.  
The most promising results were obtained with CD19 targeted CARs in hematological 
malignancies. (118) Adverse events include B cell aplasia, as CD19 is a B cell lineage 
marker, and neurotoxicities. (119) Recently CD19 CAR T cells got approved by the FDA for 
treatment of relapsed and refractory acute lymphoblastic leukemia and non-Hodgkin 
lymphoma.  
Immune checkpoint inhibition 
The discovery and characterization of inhibitory receptors on T cells enabled the 
development of T cell targeted immunotherapies. Several monoclonal antibodies targeting 
two distinct inhibitory signaling pathways, CTLA-4 and the PD-1/PD-L1 axis, in T cells have 
been approved for treatment of advanced tumors. 
T cell priming and activation is dependent on both, stimulation via the TCR and through co-
stimulatory signaling via CD28. CTLA-4 is an inhibitory receptor on T cells and a homolog 
to CD28, a co-stimulatory receptor important during T cell activation and priming. (120) 
Strong stimulatory signals result in the upregulation of CTLA-4 and consequently T cell 
anergy. (120, 121) In contrast to CTLA-4, the inhibitory receptor PD-1 is expressed on 
antigen experienced T cells, often referred to as exhausted. (122) PD-1 is often expressed on 
tumor-infiltrating T cells. (123) The ligand PD-L2 is mainly expressed on antigen presenting 
cells (APCs) and monocytes, while the expression of PD-L1 can also be induced on tumor 
cells and stromal cells in an inflammatory environment. (124, 125) Similar to CTLA-4 
signaling, PD-1 signaling inhibits T cell activity and is important for maintenance of 
peripheral tolerance. (126)  
In preclinical studies, both blockade of CTLA-4 and PD-1 resulted in rejection of tumors and 
prolonged survival. (127, 128) Blockade of CTLA-4 in patients with advanced melanoma 
induced durable responses and significantly prolonged OS. (7, 129-131) The development of 
a CTLA-4 blocking antibodies was a great success and induced previously unseen durable 
responses in a small fraction of patients with metastatic melanoma. In 2011, CTLA-4 
blockade was approved by the FDA in advanced malignant melanoma. However, severe 
toxicities were reported in all clinical trials. It was shown that CTLA-4 inhibition broadens 
the peripheral T cell repertoire and potentially releases auto-reactive T cells causing 
autoimmune reactions. (132) In contrast to CTLA-4 blockade, inhibition of PD-1 resulted in 
higher response rates and longer survival. (9, 133, 134) In addition, the treatment was 
accompanied with less severe side effects. Response to PD-1 blockade was reported in 
several cancer types including melanoma, non-small cell lung cancer (NSCLC), and RCC. 
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(135, 136) Several PD-1 and PD-L1 blocking antibodies have received clinical approval. 
Despite the great success of checkpoint inhibition for treatment of advanced tumors, 
mechanisms of resistance, both intrinsic and acquired, have been revealed. (137) Failure to 
respond to therapy is categorized as either primary or acquired resistance. Primary resistances 
to anti-PD-1/-L1 therapy are associated with low tumor PD-L1 expression and low degree of 
T cell infiltration. Response-rates are also lower in tumors that harbor low levels of somatic 
mutations. Furthermore, recent studies show that the diversity and composition of the gut 
microbiome influences the responses to anti-PD-1 therapy. (138, 139) 
Recent results show that patients that develop acquired resistance to anti-PD-1 therapy have a 
higher frequency of T cells that have gained the expression of alternative immunological 
checkpoints including; TIM-3, LAG-3, VISTA. (140) This has encouraged the launch of an 
overwhelming number of clinical trials to combine anti-PD-1 therapy with other forms of 
immunotherapy as well as conventional therapies. Secondly, analyses of tumors from patients 
that progressed on anti-PD-1 treatments have revealed that defective interferon-signaling and 
antigen presentation can occur. (141) Current research focuses on understanding resistance 
mechanisms, ultimately aiming to develop new therapeutic strategies to overcome resistance 
to treatment.  
 
1.2.3 Cancer-Immunity Circle 
The cancer-immunity circle describes the key steps essential for the generation of an anti-
tumor immune response and successful elimination of tumor cells by immune cells. (142) 
The cycle includes 7 individual steps represented in Figure 3.  
Antigen presentation by professional APCs and the priming of CD4+ and CD8+ T cells occurs 
in the draining lymph node. An inflammatory environment and immune stimulatory signals 
are essential to overcome tolerance at this stage. Once T cells are primed and activated they 
have to migrate to and infiltrate into the tumor. In the tumor microenvironment, the primed 
and activated T cells have to encounter their tumor antigens presented on the tumor cells, in 
order for them to kill the tumor cells. Dying tumor cells are then releasing tumor-associated 
antigens that can be phagocytized by APCs and again presented to T cells in the lymph node. 
The cycle of anti-tumor stimulation is endless and allows for constant generation of tumor 
specific T cells. However, we know that tumors are able to evade immune recognition. (81, 
99) Immune escape of tumor cells can occur at each step and mechanisms of immune evasion 
at each step of the cancer-immunity cycle have been reviewed by Chen and Mellman. (142) 
The development of multifaceted immune therapeutic strategies is essential to overcome 
tumor escape mechanisms. It is crucial to identify these immune evasion mechanisms within 
a tumor to combine immunotherapies successfully.  
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Figure 3: Cancer-immunity circle (adapted from Chen and Mellman, 2013) (142) 
 
1.2.4 Tumor immune profiles 
Cancer is caused by genetic alterations and while mutations can change protein functions, 
they are also reflected in the epitopes presented on MHC class I and II on tumor cells. 
Neoantiges may be recognized by tumor reactive T cells as they are foreign and tumor 
specific. The presentation of neoantigens on MHC class I and II was first described in murine 
tumor models. (143, 144) Even though only a fraction of mutated antigens is immunogenic, a 
protective tumor directed, neoantigen specific, T cell response was induced in mice. (145-
148) Neoantigens and neoantigen-reactive T cells have been identified in human tumors. 
(149) Two recent clinical trials evaluated the therapeutic potential of neoantigens. (150, 151) 
Patients with advanced melanoma were immunized with RNA or peptides corresponding to 
patient derived neoantigens. Clinical responses were observed in both studies and neoantigen-
reactive T cells were found in the blood post vaccination. Even though the mutational load 
strongly differs between tumor types and the mutanome (repertoire of mutations) is unique 
for each patient, it has become apparent that patients with high mutational load respond better 
to PD-1/PD-L1 blockade. (61, 152-155) This discovery has led to the approval of anti-PD-1 
for tumors with microsatellite instability (MSI) or mismatch repair deficiency (dMMR). (156-
160) MSI is caused by dMMR and results in high mutation burden in cancer.  
Response to PD-1/PD-L1 blockade is highly dependent on a pre-existing anti-tumor immune 
response and neoantigens appear to contribute strongly to this. (161) Nevertheless, 
approximately one third of patients have long lasting responses after PD-1/PD-L1 blockade, 
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independently of the tumor mutational load. (162) The tumor immune profiles proposed by 
Chen and Mellman may explain the differences in response to PD-1/PD-L1 blockade within 
one tumor type. (163) It has become evident, that tumors exhibit heterogeneous immune 
phenotypes. Immune profiling of tumors by IHC revealed three distinct patterns correlating to 
response to PD-1/PD-L1 blockade. (161, 164, 165) Localization of immune subsets within 
the tumor is an important criterion for treatment response. Solid tumors consist of the 
parenchyma, containing the transformed cells, and the surrounding stroma. The identified 
profiles are: immune-inflamed, immune-excluded and immune desert (Figure 4). (163) These 
immune phenotypes are not determined by the tumor type, but rather by genetic and 
environmental factors.   
 
 
Figure 4: Tumor immune phenotypes (adapted from Chen and Mellman, 2017 ) (163) 
 
Inflamed 
The immune-inflamed phenotype is characterized by an abundance of CD8 and CD4 T cells 
in the parenchyma. Immune regulatory cells like Tregs and suppressive myeloid cells are 
present as well. (161, 166-173) Expression of PD-L1 is often high on the immune infiltrating 
cells. (161, 170, 171, 174, 175) The parenchyma is enriched for inflammatory cytokines and 
chemokines. (161, 170, 171, 173) This profile suggests a pre-existing tumor directed immune 
response with recognition of the tumor by T cells. Based on the characteristics of the profile, 
tumors belonging to this prolife are suitable candidates for treatment with PD-1/PD-L1 
blockade. Indeed, several studies have shown that the majority of patients responding to PD-
1/PD-L1 blockade have inflamed tumors. (161, 168, 171, 176) However, response to this 
treatment is not guaranteed, as many other factors in the local environment may affect the 
activation of tumor reactive T cells.  
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Immune-excluded 
In contrast to inflamed tumors, lacks the parenchyma of immune-excluded tumors immune 
cell infiltration. CD8 and CD4 T cells as well as myeloid cells are present in the tumor, but 
localized in the stroma surrounding the parenchyma. (161, 165, 177, 178) The cause of this 
typical lack of infiltration into the tumor parenchyma has been explained in different ways. 
(177-179) While checkpoint inhibition still activates the tumor reactive T cells, they’ll be 
unable to infiltrate and leave the stroma. Clinical responses are consequently rarely seen. 
(161) Anti-VEGF antibodies in combination with checkpoint inhibition are able to increase T 
cell infiltration into tumors, through increase of chemokines in circulation and upregulation 
of adhesion molecules on tumor vasculature. (180-182) 
Immune-desert 
Tumors with immune desert phenotype lack T cells completely in the parenchyma. Myeloid 
cells can be present in the tumor. (161, 164, 165, 167) It appears that tumors with this 
phenotype completely lack a tumor-directed immune response. (163) Tumors with this 
phenotype seldom respond to PD-1/PD-L1 inhibition. (161) 
Treatment regiments for this tumor profile must aim to both elicit a tumor directed immune 
response and ensure antigen presentation by tumor cells. Until today, patients with tumors of 
immune-desert phenotype have very poor prognosis and respond poorly to immune therapy. 
Therapeutic vaccines could fill this gap, able to elicit de novo immune responses directed 
against a great number of possible antigens including neoantigens. (183) 
 
1.3 CANCER VACCINES 
One possibility to elicit a tumor directed immune response is by using vaccines. Vaccines are 
potent generators of novel, and enhancers of pre-existing, immune responses and have been 
highly effective in preventing infectious diseases. In cancer treatment, however, vaccines 
have not yet been successful. In contrast to infectious diseases, tumors are in the majority of 
cases not caused by foreign infectious agents. Hurdles for cancer vaccines are immune 
suppression by the tumors themselves or the cells within the tumor microenvironment. (184-
186) The decrease of vaccination efficacy with tumor progression is illustrated in Figure 5. 
Cancer vaccines can be divided into prophylactic and therapeutic vaccines. Prophylactic 
vaccines are of interest when cancer development should be prevented. Unlike therapeutic 
vaccines, prophylactic vaccines are administered in healthy individuals. Two prophylactic 
cancer vaccines targeting the viruses HBV and HPV, known to cause live cancer and 
cervical, have been FDA approved. Both HBV and HPV vaccination prevents latent infection 
of the host with the virus. Incidence rates of HCC decreased strongly upon approval of HBV 
vaccination. (187) The first HPV vaccination was only approved in 2006, but a decreased 
incidence of cervical carcinomas has already been reported. (188)  
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Figure 5: Impact of tumor burden on vaccination efficacy (adapted from Lollini et al. 2006) (189) 
 
The idea of using vaccines in cancer therapy is not novel. Already in 1891, William Coley 
made the observation that some patients, who got bacterial infections after surgery, showed 
spontaneous tumor regressions. Based on his observations, he treated inoperable sarcoma 
patients by intratumoral injection of Streptococcus pyogenes and Serratia marcescens, now 
known as the Coley toxin, to stimulate their immune system. (190, 191) However, his work 
was highly controversial at that time. In bladder cancer, intravesical instillation of the BCG 
vaccines is standard adjuvant treatment. (192-194) The BCG vaccine contains live attenuated 
Bacillus Clamette-Guérin and acts on the same principles as the Coley toxin.  
From a therapeutic cancer vaccine perspective neither the BCG vaccine, nor the Coley toxin, 
are considered specific vaccines. Both act as immune stimulants, but don’t aim to generate a 
tumor specific immune response. It has been a great effort to identify tumor specific vaccine 
targets and platforms that elicit strong tumor directed immune responses. Therapeutic cancer 
vaccines are commonly categorized based on their formulation into cell based vaccines, 
protein/peptide vaccines, and genetic vaccines. Each formulation has its own advantages and 
disadvantages (Table 1). 
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Table 1: Advantages and disadvantages of vaccine formulations 
 •  Advantages Disadvantages 
cell based vaccines 
(autologous, 
allogeneic and DC 
vaccines) 
•  • Vaccination with full  
antigen spectrum if loaded 
with tumor lysate 
• Tumor antigens can be 
unknown 
• No HLA restriction† 
• Personalized 
• DCs are potent APCs 
• Work intensive 
• Autologous tumor cell 
vaccines require large 
amounts of primary tumor 
• Monitoring of immune 
response is challenging since 
antigens are unknown† 
peptide/protein 
vaccines 
•  • Off the shelf 
• More cost effective than 
cell based vaccines 
• Immunogenic epitope needs 
to be present within peptide 
sequence (potential HLA 
restriction) 
• Not immunogenic by 
themselves 
genetic vaccines •  • Cost efficient production 
• Easy manufacturing process 
• Can be immunogenic by 
themselves 
• Antigen can be unknown 
• Risk of anti-virus immune 
response when viral vectors 
are used for packaging 
†except for DCs loaded with HLA-restricted peptides 
 
1.3.1 Cell based vaccines 
Tumor cell vaccines (autologous and allogeneic) and DC vaccines belong to the cell based 
vaccines. For autologous tumor vaccines, patient derived tumor cells are irradiated and 
inoculated into the same patient usually together with adjuvants. Autologous tumor cell 
vaccines have been among the first cancer vaccines to be tested in a range of different tumor 
types. (195-201) The great advantage of autologous tumor cell vaccines is that they include 
the whole spectrum of antigens expressed in the tumor piece that was used for vaccine 
preparation. There is no need to identify immunogenic peptides. However, these vaccines are 
highly personalized and require large amounts of resectable tumor tissue. (202) 
Allogeneic tumor cell vaccines are similar to autologous cancer vaccines but differ in the 
source of antigen. Several established tumor cell lines, with known antigen expression are 
used for vaccination. This allows for standardization and off-the-shelf vaccines. (202)  
A disadvantage is of course that the antigen profile of the vaccine might not fit optimally to 
the patients’ tumor antigen profile. (203) Although, allogeneic tumor cell vaccines are more 
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immunogenic and have been tested in different tumor types including melanoma, prostate, 
and lung cancer. (204-209)  
Dendritic cells (DCs) are professional APCs and potent elicitors of anti-tumor immune 
responses. For vaccination, autologous DCs are generated ex vivo from precursor cells 
derived from the patient’s blood. Before re-infusion, they are loaded with tumor antigens and 
matured. DCs can be loaded with a great range of material, including tumor lysates, tumor 
cell lines, proteins and peptides. (210) It has become apparent that DC subsets vary in their 
ability to elicit strong immune responses. A lot of focus has been put on identifying methods 
to generate potent DCs for vaccination. (211, 212) Potent DCs need to express co-stimulatory 
molecules (CD40, CD80, CD86) and secrete cytokines to enhance T cell response. (213) 
Sipuleucel-T is an FDA approved DC vaccine in prostate cancer. Monocytes are loaded with 
a fusion protein of prostate tumor antigen PAP and GM-CSF. While the first clinical trials 
only showed minor anti-tumor efficacy, new studies are conducted in advanced prostate 
cancer for combinations with endocrine therapy and chemotherapy. (8, 214)  
 
1.3.2 Peptide vaccines 
Peptide vaccines have a clear advantage over the cell based vaccines, as they are universal. 
Due to the low immunogenicity of proteins and peptides, potent vaccines should include 
immune stimulatory adjuvants. One limitation of peptide vaccines is their MHC class I 
restriction. The peptides used for vaccination contain epitopes recognized by CTLs. Peptide 
vaccines can only elicit an immune response, if the epitopes within a peptide can be presented 
on the patient’s MHC class I molecules. Consequently, the number of patients benefiting 
from peptide vaccines is limited to those expressing epitope binding MHC class I molecules.  
Over the past decades a number of TAAs with CTL epitopes have been described, i.e. gp100, 
MAGE-1, MART-1, CEA, MUC-1 and PAP. (215-220) 
One of the first peptides that was used as a vaccine antigen was gp100. gp100 contains a 
HLA-A2 specific peptide between amino acid 209-217. Reactivity towards this epitope was 
confirmed in vitro for HLA-A2+ melanoma patients. (221) In phase II clinical trials, gp100 
vaccination were tested together with high does IL-2 treatment in advanced melanoma 
patients. Vaccination elicited CTL responses in patients with advanced melanoma, but did not 
have clinical benefit. (222) In a follow up trial, the vaccine was injected together with 
incomplete Freud’s adjuvant and high does IL-2 treatment. The adjuvant increased the 
response rate and prolonged progression free survival (PFS). (223) Clinical responses to 
vaccines can be increased by targeting multiple antigens. Efficacy of a multi-peptide 
vaccination in HNSCC was evaluated in a phase II clinical trial. Vaccination prolonged OS 
from 3.5 to 4.9 months. More interestingly, patients with CTL reactivity to multiple peptides 
had better clinical responses than patients with single reactivity. (224)  
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The results of these trials show that peptide vaccines are able to induce antigen specific CTL 
responses. Adjuvants and the inclusion of multiple peptides can boost the vaccine efficacy 
and result in clinical benefit.  
 
1.3.3 Genetic vaccines 
In genetic vaccines, antigens are encoded on RNA fragments or DNA plasmids. They can be 
administered naked or packaged in viral vectors.  One advantage of DNA and RNA vaccines 
is that multiple antigens can be delivered in one immunization, allowing for broader and 
stronger immunizations. (225) Viral vectors are highly immunogenic and efficient delivery 
systems for antigens. However, sequential administration of the same viral vector also 
induces a vector directed immune response. As a consequence, the virus particles are 
removed from the host before host cells can be infected and present the antigens, resulting in 
a decrease of vaccine potency. (226) In contrast to viral based vaccines, nucleic acid vaccines 
can be administered over a long period without loss of potency.  
 
1.4 DNA VACCINES 
DNA vaccines encode the antigen and are delivered intradermal or intramuscular. They 
induce an antigen specific immune response through a direct transfection of APCs and 
indirect APC activation via the transfection of somatic cells. Injection of DNA bears the risk 
of genome integration. To reduce the risk of integration to the minimum, the DNA plasmid 
should not contain a mammalian origin of replication and homology with the human genomic 
sequence should be avoided. (227, 228)  
At the injection site, the plasmid is taken up by keratinocytes and myocytes and localizes into 
the nucleus. The antigen will then be expressed by the transfected cells, processed and 
peptides will be presented on MHC class I and could directly stimulate antigen specific 
cytotoxic T cells, if present in the local environment. Crucial for a strong immune response, 
is the antigen uptake by APCs through phagocytosis of transfected cells. Antigen loaded 
APCs migrate to the lymph node, where they will present the antigen on MHC class II and 
MHC class I, through cross presentation, to CD4 and CD8 T cell, respectively. CD4 T cells 
can further induce antigen specific B cell responses. (225) Tissue resident APCs can also 
directly be transfected and activate CD4 and CD8 T cells. (229) DNA vaccines allow for 
encoding full length protein or long peptide, increasing the possibility of CD4 epitopes being 
presented on MHC class II. Activation of CD4 T cells is a crucial step in generating an 
antigen specific humoral response. (Figure 6)  
DNA plasmids are often of bacterial origin and therefore immunogenic by themselves. They 
activate toll-like receptors (TLRs) and damage-associated molecular patterns (DAMPs), 
resulting in type I interferon (IFN) responses and pro-inflammatory cytokine responses. (225, 
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230-233) Vaccination results in a local inflammation augmenting the antigen directed 
immune response. Activation of NFκB and type I IFN signaling have been identified as 
essential for successful DNA vaccination. (233-235) 
 
 
Figure 6: Mechanisms of action for DNA vaccination 
 
1.4.1 Enhance immunogenicity of DNA vaccines 
For DNA plasmids to elicit an immune response, the DNA plasmid is required to be taken up 
by the cells and transported into the nucleus. Electroporation can be used to increase the 
transfection rate in vivo. The electric field forms nanopores in the cell membrane and forms 
an electrical gradient within the cells. (236, 237) The negatively charged DNA moves 
through the electric field and enters the cells. (236) Electroporation increases the transfection 
efficacy by increasing the number of infected cells and co-transfecting cells with several 
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plasmids. (238, 239) In addition, immunogenicity of DNA vaccines was reported to be 
increased after electroporation, through local tissue damage. Inflammatory cytokines are 
secreted at the electroporation site and APC recruited. (240, 241) Finally, electroporation 
DNA vaccination was shown to increase antigen specific immune response when compared 
to DNA vaccination by itself. (242-244) Despite all these benefits, it requires a lot of 
optimization to set up electroporation protocols for optimal antigen expression and immune 
response, while avoiding greater cell damage. (245) 
Once the DNA plasmid is in the cell, optimal antigen expression is key for successful DNA 
vaccination. DNA plasmids are not replicated in the cells and therefore the antigen should be 
expressed under a highly efficient promotor. The CMV promoter is one of the most active 
promotor and was found superior to other promotors. (246) Antigen expression is affected by 
mRNA stability and translation efficacy. It is known that mRNA with great levels of AU in 
the sequence has decreased stability. (247) Consequently, are the encoded proteins less 
abundant. A second bottleneck in mRNA translation is the amount of tRNAs. tRNAs are the 
link between the mRNA and amino acid. Each amino acid binds to 2 or more tRNAs. Low 
abundancy of some tRNAs can affect protein expression. Increased immunogenicity of 
vaccination was reported when the antigen sequence was modified from low to high abundant 
tRNAs. (248-250) 
Even though DNA vaccines are immunogenic by themselves, a number of strategies have 
been evaluated to enhance antigen specific immune responses.  Co-injection of TLR and 
DNA sensor agonists has been shown to enhance anti-tumor immunity in murine tumor 
models. (251-253) Enhancing immune stimulation through fusion of microbial peptides with 
antigens has been tested in mouse models. (254, 255) In a phase I clinical trial in colon 
cancer, safety of a CEA-tetanus toxoid CD4 epitope was investigated. (256) No anti-tumor 
efficacies were evaluated. Safety of co-injection of GM-CSF and IL-2 together with DNA 
vaccination was examined in a trial in metastatic breast cancer. (257) Vaccination induced 
long-term humoral and cellular responses, but clinical benefit was not evaluated. One clinical 
trial that reported clinical benefit was conducted in patients with cervical intraepithelial 
neoplasia. The vaccine targeted the viral proteins E6 and E7 of HPV-16 and 18. Patients 
receiving the vaccine in this double blinded placebo trial had increased rates of local infection 
and regression. (258)  
 
1.5 THERAPEUTIC CANCER VACCINES IN MELANOMA AND BREAST 
CANCER 
Efficacy of therapeutic cancer vaccines has been evaluated in both melanoma and breast 
cancer. Several vaccine trials in advanced melanoma have been performed at the NCI 
Surgery Branch, mostly peptide vaccines targeting melanoma antigens. Despite these great 
efforts, the objective response for all trials together was only 2.6 %. (259) In 2011, results 
from a trial combining gp100 peptide vaccination with IL-2 in patients with advanced 
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melanoma reported prolonged PFS. (223) Combination of gp100 peptide vaccination with 
CTLA-4 blockade did not have any synergistic effect. (7) In 2015, FDA approved T-VEC, an 
oncolytic virus producing GM-CSF, for treatment of patients with advanced non-resectable 
melanoma. The phase III clinical trial that led to the approval of T-VEC, durable responses 
were observed in 16% of the patients and only 25% in the control arm. (260) In 2017, results 
from two vaccine trials targeting neoantigens reported clinical responses in patients with 
advanced disease.  (150, 151)  
Significantly less vaccine trials have been performed in breast cancer. Similar to the studies 
in melanoma were peptide vaccine most commonly tested, targeting HER2 or MUC-1 among 
others. The majority of the vaccines has been tested in disease free patients. Although antigen 
specific immune responses were elicited, only minor clinical benefit was observed. (261-267)  
 
1.6 CHALLENGES IN CANCER VACCINE DEVELOPMENT 
The field has faced three major challenges, (i) the systemic immune suppression in cancer 
patients, (ii) the lack of suitable antigens, (iii) monitoring of efficacy. When analyzing cancer 
vaccine trials retrospectively these challenges are likely the reason why the trials failed.  
Monitoring of vaccine efficacy 
Clinical trials in cancer have classically been evaluated based on ‘hard’ criteria. Treatment 
response in the clinical trials was assessed and determined based on the RECIST criteria, 
evaluating tumor shrinkage. (268) Tumor shrinkage as response criterion has been 
appropriate for therapeutic agents directly targeting tumor cells. However, with the 
development of immunomodulatory drugs and cancer vaccines, these criteria have been 
found to be less appropriate. Additional evaluation criteria for objective response have been 
suggested including patient survival, progression free survival, and stable disease.  (259, 269, 
270) Based on the development in the field of cancer immunotherapy the RECIST criteria 
have been updated in 2009. (271) 
Immune suppression 
Vaccination trials are often performed in late stage patients. Systemic immune suppression 
dampens the vaccine efficacy and limits the elicited immune response, while the local tumor 
microenvironment inhibits the anti-tumor directed immune response within the tumor. The 
MUC1 peptide vaccination was tested in both early and late stage colon cancer patients, 
which allows us to draw conclusions on the impact of advanced tumors on anti-tumor 
immunity. (272) While vaccination in patients with adenocarcinoma elicited minor MUC1 
specific responses, the vaccination in a subset of patients with advanced adenoma induced 
strong humoral responses. (272, 273) Response to vaccination was inversely correlated to 
circulating myeloid derived suppressor cells, an indicator of systemic and local immune 
suppression in cancer. (273)  A phase I DNA vaccination trial in melanoma targeting both 
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TRP2 and gp100 found that vaccination induced a stronger immune response in patients 
without tumor present at the time of vaccination than in patients with tumor burden. (274) 
Patient selection and adjustments to these conditions in the vaccination setting can be the 
solution for this problem.  
Antigen selection 
Cancer vaccine antigens are typically categorized based on their biological origin in the 
following categories: 1) Oncoproteins, 2) Oncofetal, 3) Tissue differentiation, 4) Viral, 5) 
Stem cell/EMT antigens, and 6) Others. (183) A comprehensive list of human tumor antigens, 
reported to be recognized by T cells, was published by Renkvist et al in 2000 and was 
updated by Novellino et al. in 2004. (275, 276)  
Antigen selection is a critical step in the development of cancer vaccines. An antigen needs to 
fulfill a number of requirements in order to be a suitable target for vaccination. Vaccine 
antigens need to be exclusively expressed on tumor tissue with low or no expression in 
healthy tissue. The antigen should also be immunogenic and expressed on the cell surface, to 
be targetable both by cellular and humoral immunity. For cancer vaccine antigens, it is also of 
interest if the protein is involved in key mechanisms of cancer progression. Targeting of these 
proteins, may not eradicate tumors completely, but at least halt progression. Proteins 
associated with the EMT process and cancer stem cells, have therefore been under 
investigation as suitable targets for cancer vaccines. Two phase I vaccine trials with vaccines 
targeting T-box transcription factor Branchury, a driver of EMT, have shown safety of the 
vaccines and presence of Branchury specific T cells after vaccination. (277-279) Prophylactic 
vaccination with irradiated induced pluripotent stem cells controlled tumor growth in murine 
mammary carcinoma and melanoma models. (280) No clinical trials targeting stem cell 
specific antigens have been performed yet.  
Identification of suitable targets is a hurdle within the cancer vaccine field. An algorithm to 
stream line antigen identification has been proposed and tested. (281) The algorithm will 
allow for identification of candidate targets based on functional and immunogenic criteria, 
including expression level, specificity, number of antigenic epitopes and cellular location. 
(281)  
Combination therapy  
Selection of the study cohort is an essential step in clinical trial design and has a strong 
impact on clinical outcome. Many vaccine trials have been performed in late stage patients. 
We know today that patients with advanced carcinomas are often systemically immune 
suppressed. In several clinical trials, it was found that large tumor burden decreases the anti-
tumor efficacy of vaccines. (272-274, 282) 
Combination of cancer vaccines with other treatments can potentially enhance efficacy and 
clinical benefit. Classical cancer treatments like chemotherapy and irradiation have been 
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found to have additional immune stimulatory effects besides their anti-tumor activity. (283, 
284) Some forms of chemotherapy and in particular at low dose, has been shown to synergize 
with cancer vaccines in clinical trials. (207, 285, 286) The impact of chemotherapy and 
radiotherapy on cancer vaccines in preclinical and clinical trials has been discussed by Hodge 
et al. and Andersen et al. (287, 288) Cancer vaccines have also been tested in combination 
with checkpoint inhibition. PD-1 inhibition resulted in complete responses in two stage IV 
melanoma patients that relapsed after personal neoantigen vaccination. (150) The T-VEC 
vaccine has been combined with both anti-CTLA-4 and anti-PD-1 inhibition and tested for 
efficacy in patients with advanced melanoma. Both trials reported increased objective 
response rate for the combination of T-VEC with immune checkpoint inhibition over 
checkpoint blockade alone. (289, 290) 
Cancer vaccines are often combined with GM-CSF, a potent immune stimulator through 
activation and maturation of DCs. (291) GVAX is a GM-CSF secreting tumor cell based 
vaccine. (209, 292, 293) It has been tested in several cancer types including melanoma, 
prostate and, pancreatic cancer. (294-296) Combination of GVAX in advanced pancreatic 
cancer with CTLA-4 inhibition was found to increase survival over CTLA-4 inhibition alone. 
(297) A vaccine consisting of mutant ras peptides given in combination with GM-CSF 
elicited clinical responses in patients with advanced pancreatic cancer, which correlated with 
the induced antigen immune response. (298) However, another trial showed that addition of 
IL-2 to the vaccine regiment diminished the effect of vaccination with mutant ras peptides 
and GM-CSF alone. (299) The results show, that multi-combination trials with cancer 
vaccines can be inferior to single combinations.  
Combinations of cancer vaccines with other immunomodulatory agents targeting IDO, OX40 
and GITR have been tested in pre-clinical tumor models and show promising results. (300-
303) 
 
1.7 CRIPTO-1 
Cripto-1 (Cr-1) is a glycoprotein and was first cloned in 1989. (304) It is a membrane bound 
protein, anchored to the cell membrane with GPI, but can also be shed when the anchor is 
cleaved by GPI-phospholipase D. (305, 306)  Cr-1 belongs to the EGF-CF protein family. 
(307) Members of this family are essential during early embryogenesis, implicated to be 
involved in the regulation of germ layer formation and the orientation of anterior posterior 
axis. (308, 309) In adult tissue, Cr-1 is expressed in low levels. (310, 311)  
Lacking an intracellular domain, Cr-1 is a co-receptor in the activation of intracellular 
signaling by Nodal and other TGFβ family member, Glypican-1, and Wnt family members. 
(312-315) During embryogenesis these signaling pathways activate cell proliferation, 
survival, migration and differentiation (Figure 7). (312, 313)  
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Figure 7: Cripto-1 signaling pathways (Adapted from Bianco et al., 2004) (312) 
 
1.7.1 Role of Cripto-1 in cancer 
It is known that there are many parallels between embryogenesis and tumor development. 
Conserved signaling pathways for cell proliferation, plasticity and motility during 
embryogenesis are often reactivated in cancer and critical for tumor progression. (316) 
Similar to other embryogenic proteins found to be re-expressed in cancer, Cr-1 expression 
has been identified using qPCR and IHC in a great number of human tumors. (317-319) An 
overview is presented in Table 2.   
In particular, high expression of Cr-1 was correlated with worse prognosis is breast cancer, 
HCC, and glioblastoma. (320-323) A study in bladder cancer described not only the 
correlation of high Cr-1 expression with shorter OS and PFS, but also a positive correlation 
between Cr-1 expression and tumor grade. (324) While a study in a cohort of ESCC patients 
did not evaluate survival, they did find a correlation between Cr-1 expression and tumor 
grade. (325) A survival study in lung adenocarcinoma correlated high expression of Cr-1 
within the tumor, together with high serum levels of the lung cancer tumor marker CEA, with 
poor prognosis in lung adenocarcinoma. Cr-1 was found to correlate better with shorter 
survival than CEA serum levels did. (326) In a study on gastric cancer, Cr-1 expression was 
evaluated together with e-cadherin, a protein which is associated with epithelial cells and lost 
during EMT. Patients with low expression of e-cadherin and high expression of Cr-1 had the 
worst prognosis in this cohort. (327) 
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Table 2: Summary of Cripto-1 expression in human tumors 
Tumor type Subtype 
Method of 
detection 
Reference 
Breast cancer  IHC, ICC (320, 328, 329) 
Bladder cancer  IHC (330) 
Brain tumors Glioblastoma mRNA, IHC (322, 323) 
Cervical cancer  IHC (331) 
Colorectal cancer  IHC (332-334) 
Endometrial cancer  IHC (335) 
Gall bladder cancer  IHC (336) 
Gastric cancer  mRNA, IHC (327, 337) 
Hepatocellular carcinoma  IHC (321) 
Lung cancer NSCLC, LAC IHC, mRNA (326, 338, 339) 
Melanoma cutaneous & uveal IHC (340, 341) 
Pancreatic cancer  IHC (342, 343) 
Ovarian cancer  IHC (344-346) 
 
Cr-1 can also be shed from the extracellular surface. In a number of different studies, Cr-1 
protein was detected in the sera of patients, while only low levels were found in healthy 
controls. (347-349) In breast cancer, colon cancer, and HCC, levels of soluble Cr-1 (sCr-1) 
were not correlated with stage of disease. (347, 349) Interestingly, sCr-1 levels have been 
associated with worse prognosis and shorter survival in patients with NSCLC and 
glioblastoma multiforme. (323, 350, 351) 
Until today, it remains unclear why Cr-1 is linked to poor prognosis and tumor stage in some 
tumor types while not in others. The fact that Cr-1 is found to be present in a large number of 
different tumor types, suggests that the function of Cr-1 within tumors is independent of the 
tumor type and rather specific for certain phenotypes of tumors. In conclusion, several studies 
have investigated Cr-1 in different tumors and cancer cell lines, allowing us to draw 
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preliminary conclusions on the functions of Cr-1 in cancer. Expression of Cr-1 was in 
particular linked to EMT and the presence of cells with stem cell phenotype within tumors.  
 
1.7.2 Cripto-1 and epithelial-mesenchymal transition 
Cr-1 has been implicated to play a crucial role in the EMT process during the germ layer 
formation facilitating signaling of TGF-β and Wnt family members. (352) Wnt/ β-catenin 
signaling is known to be involved in EMT and cell plasticity both in embryogenesis and 
cancer. (353) Knockout of Cr-1 causes embryonic lethality at day 7.5, unable to form 
mesoderm and endoderm. (354) Crosstalk of Cr-1 with Wnt in the EMT process has been 
shown during mouse embryonic development. Wnt -/- and β-catenin -/- results in similar 
phenotype as for Cr-1 knockout. (355) Knockout of Wnt3 in particular, resulted in reduced 
expression of Cr-1 implicating a regulation of Cr-1 expression downstream of Wnt3a 
signaling. (355, 356) The role of Cr-1 in EMT in cancer has been studied in the Cr-1 
overexpressing MMTV mammary carcinoma model. (357) Overexpression of Cr-1 induced 
EMT-like morphological changes and resulted in increased migration and invasion resulting 
in development of hyperplasia and adenocarcinoma in the MMTV model. Within these 
tumors, an increase in mesenchymal proteins was detected, while proteins associated with 
epithelial cells were decreased. (357-359) In addition, studies in melanoma cell lines have 
shown that Cr-1 enhanced cell motility in vitro via Nodal and src signaling. (340) 
 
1.7.3 Cripto-1 and cancer stem cells  
It has become evident, that EMT and stem cell phenotype are tightly linked cellular 
programs, both in stem cell and in epithelial cell populations. (45, 360, 361) Cr-1 itself has 
been found to link EMT to stem cell phenotype in cells. Cr-1hi expressing cells within the 
NTERA2/DC EC cell line displayed an EMT phenotype and enhanced capacity to form 
spheroids in vitro, when compared to the Cr-1low subpopulation. (362) 
Cr-1 can also regulate stem cell phenotype. It was shown that Cr-1 is critical for the 
maintenance of pluripotency in human end mouse embryonic stem cells. (363) In a number of 
recent studies, the role of Cr-1 in CSCs has been explored. In colorectal cancer, Cr-1 has been 
found to regulate the CSC compartment. (364) For CSC like cells in esophageal squamous 
cell carcinoma, Cr-1 is a functional marker correlated to patient outcome. (365) While Cr-1 is 
known to be linked to poor prognosis, the mechanism was still unclear. (321) In a recent 
study, the role of Cr-1 in CSC within HCC was further explored. It was found that Cr-1 
enhances Wnt signaling by stabilizing Dvl3, resulting in strong activation of β-catenin. (366) 
In addition, it has become clear that Cr-1 is part of the stem cell gene network. Cr-1 is a direct 
target of the transcription factors Nanog and Oct4. (367-369) This regulation has been 
confirmed in human embryonal carcinoma cells. (362) Within stem cells, Cr-1 mediated 
Nodal signaling induced transcription of Nanog, creating a positive feedback loop. (367, 368) 
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It remains to be shown, that this feedback loop is involved in maintenance of stem cell 
phenotypes in tumor cells. Expression of Cr-1 has been described in CSCs in both melanoma 
and in colorectal cancer. (364, 370)  
Based on our knowledge of Cr-1 within a great signaling network regulating both cell 
proliferation and EMT, we suspect Cr-1 to be involved in tumor development and 
progression. The association of Cr-1 with EMT processes may explain why Cr-1 is associated 
with poor prognosis. CSCs and cells with stem cell phenotype have been shown to be 
resistant to classical cancer treatments, including chemo-and radiotherapy. (371) The 
expression of Cr-1 in especially in these subsets of tumor cells, implicates the importance of 
Cr-1 in treatment resistance and relapse. 
Taken together, these findings propose that Cr-1 is an interesting candidate for cancer 
immunotherapy with the potential to control hallmarks of aggressive tumors. Thus both 
distant spread, by blocking EMT, and relapse post treatment, by targeting CSCs, may be 
reduced.  
 
1.7.4 Potential of targeting Cripto-1 in cancer  
Due to its important biological function in cancer, Cr-1 is not a novel target in cancer therapy. 
A number of different therapeutic strategies have been evaluated for efficacy in murine tumor 
models.  
Cr-1 antisense oligonucelotides bind Cr-1 mRNA and inhibit the translation. Antisense 
oligonucleotides to Cr-1 have suppressed growth of human breast, ovarian and colon cancer. 
(372-374) A follow up study in colon xenograft models showed that injection of multiple 
antisense oligonucleotides targeting growth factors including Cr-1 inhibited tumor growth. 
(374) 
In addition to antisense oligonucleotides, Cr-1 binding therapeutically active antibodies have 
been developed and tested in vitro as well as in xenograft models. Antibodies targeting 
different epitopes of the Cr-1 protein have been developed. By blocking the assembly of Cr-1 
in receptor complexes, downstream signaling was inhibited and tumor growth controlled. 
(375-378) One Cr-1 specific antibody conjugated to the cytotoxic component DM4 has been 
tested in a Phase I clinical trial (NCT00674947). The results of this study have not been 
published yet. Apart from this antibody, no other Cr-1 targeting treatment has been tested in 
the clinic so far.  
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2 AIMS OF THE THESIS 
 
The thesis has evolved around the tumor associated antigen Cr-1. Based on the previous 
studies on the presence and function of Cr-1 in human tumors, we identified Cr-1 as a 
valuable target for aggressive cancers. In contrast to previous studies, we have investigated 
this protein in cancer from an immunological point of view. In study I and II we evaluated the 
immunogenicity of Cr-1 upon DNA vaccination with Cr-1 in two mouse strains. Study III is a 
translational study in which we assessed the presence of sCr-1 protein and Cr-1 specific T 
cells in the blood of human advanced melanoma. Taken together, the findings presented in 
this thesis highlight the relevance of Cr-1 as a protein of interest in cancer immunotherapy.  
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3 RESULTS & DISCUSSION 
 
3.1 STUDY I 
Cripto-1 vaccination elicits protective immunity against metastatic melanoma 
 
Background 
Checkpoint inhibitors targeting CTLA-4 or the PD-1/PD-L1 axis have induced long lasting 
responses, in particular in melanoma. (131, 379) However, it has become evident that large 
numbers of patients with metastatic disease will not response or relapse. (7, 162, 380, 381) 
One reason why patients are resistant to treatment with checkpoint inhibitors is the lack of 
tumor reactive T cells. This has been shown to be caused by a general absence of tumor 
antigens or insufficient antigen presentation. (382) Vaccination is a therapeutic strategy to 
generate de novo, and boost existing tumor antigen specific T cells. One bottle neck in cancer 
vaccine development has been the lack of suitable targets. The oncofetal protein Cr-1 is part 
of cellular signaling pathways during embryogenesis inducing EMT, migration and invasion. 
(383) These processes constitute hallmarks of aggressive cancers. (1) The expression of Cr-1 
was reported in a large number of human cancers. (384) Based on its biological function and 
tumor specific expression we identified Cr-1 as a suitable target for vaccination in cancer 
therapy.  
Aim of the study 
The intention of this study is to assess if murine Cr-1 (mCr-1) is an immunogenic antigen and 
if mCr-1 DNA vaccination can elicit a mCr-1 directed immune response. In addition, we 
address the question, if the elicited immune response is anti-tumor directed and protective in 
a murine melanoma model.  
Results 
We assessed the immunogenicity of mCr-1 through identification of potential CD8+ T cell 
epitopes. Using an overlapping peptide library (15-mer), covering the full length mCr-1 
protein, and in silico epitope prediction tools, we identified three candidate peptides (9-mers). 
All candidate peptides stabilized H2-Kb on RMA-s cells.  
Mice were vaccinated at week 8 and 10 by intradermal injection of full length mCr-1 
encoding DNA plasmid (pmCr-1), or empty plasmid as control (pVAX-1), followed by 
electroporation of the injection site. Immunization-induced immune responses were evaluated 
14 days after the second injection. T cell activation within splenocytes from pmCr-1 and 
pVAX-1 immunized mice were evaluated in vitro. Only peptide mCr-116-25 strongly activated 
cytotoxic T cells from pmCr-1. This finding was confirmed in an in vivo cytotoxicity assay.  
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Based on these findings we hypothesized that Cr-1 vaccination elicits Cr-1 peptide 
recognizing cytotoxic T cells in C57Bl/6 mice. If Cr-1 is indeed a relevant tumor antigen in 
cancer, we proposed that Cr-1 vaccination can control tumor growth. We chose to test this 
hypothesis in the syngeneic murine melanoma model B16F10. The B16F10 cell line gives 
rise to aggressive tumors in vivo and is widely used to study solid tumors, when injected s.c., 
and metastases, when injected i.v.. Cr-1 expression in the B16F10 cells was confirmed by 
western blot. After prophylactic vaccination, mice were challenged with s.c. injected B16F10 
cells. We observed reduced tumor sizes in the pmCr-1 vaccinated group compared to the 
control group. Immunization prior to i.v. challenge with B16F10 resulted in great reduction 
of lung tumors in the pmCr-1 group.  
Significance 
In this study, we were able to confirm the potency of targeting Cr-1 in cancer therapy and 
extend this knowledge by exploring a vaccine based therapeutic approach.  
Cripto-1 has been identified and tested in other pre-clinical studies as a target in cancer 
therapy. (372-378) These strategies aimed to inhibit the signaling function of Cr-1 or its 
expression and were reported to inhibit tumor growth. One disadvantage of the suggested 
treatment strategies is that they would need to be administered continuously or for a long time 
in order to maintain tumor control. We have identified Cr-1 as a suitable target for 
vaccination. It is a cell surface expressed protein, overexpressed in tumors in comparison to 
somatic cells, and is associated with hallmarks of advanced tumors. (310) As the platform for 
antigen delivery we chose DNA vaccination followed by electroporation. DNA vaccines are 
not only easy and cost efficient in the manufacturing process, we also had previous 
experience from working with DNA vaccines. (234, 251, 257) Breaking tolerance against the 
endogenous protein Cr-1 was critical in our study. Indeed, we found that prime boost DNA 
vaccination followed by electroporation elicited Cr-1 specific CTLs and protection against 
challenge with tumor cells. The potency of homologous prime-boost DNA vaccination has 
been previously shown in other studies. (234, 385) However, it has been shown that 
heterologous vaccination regiments combining DNA vaccination with protein or viral based 
vaccination are more potent. (225) We considered combining DNA and protein vaccination 
but attempts to produce recombinant Cr-1 protein were unsuccessful and commercially 
available protein too expensive. We can only speculate that a heterologous prime boost 
vaccination, could have elicited a stronger Cr-1 directed immune response resulted in greater 
protection. In murine tumor models, internal tolerance could be overcome by xenogeneic 
DNA vaccination. (386, 387) However, clinical benefit of syngeneic over xenogeneic 
immunization was not observed in clinical trials. (388-392). Due to the lack of clinical 
relevance, we did not further explore the beneficial effects of xenogeneic vaccination in our 
study. We know from previous studies that adjuvants can enhance immunogenicity of DNA 
vaccines. (251-253) In this study we found it sufficient to perform electroporation in 
combination with DNA vaccination to elicit a Cr-1 directed immune response. We 
hypothesize that inclusion of additional agonists in the vaccine formulation would further 
 28 
increase immunogenicity of the vaccine and a potential therapeutic benefit should be 
evaluated in additional studies.  
Monitoring of immune response post vaccination is a crucial step in the evaluation of 
immunogenicity. It is therefore essential to identify immunogenic peptides that allow for 
monitoring. Overlapping peptide libraries, like we used in our study, are commonly used to 
identify MHC binding epitopes. (393, 394) Using in silico prediction we identified potential 
immunogenic epitopes with the highest binding affinity to H2-Kb within the hits of the first 
screen. However, it was not the epitope with the highest binding to H2-Kb. In line with our 
findings, a study comparing immunogenicity of high and low MHC binding peptides found 
that low affinity peptides were more potent in generating CTLs with longer avidity. (395) 
Therefore, binding affinity might not be a fully reliable marker for immunogenicity of 
epitopes. Stability of the epitope MHC class I epitope was identified as more predictive for 
CTL specific immunogenicity than epitope binding affinity. (396)  
To investigate if Cr-1 vaccination is protective we chose the murine melanoma model 
B16F10. The B16 and B16F10 murine melanoma models are widely used syngeneic 
melanoma models, especially in vaccine studies. (397) Despite the fact that they express 
known melanoma antigens, they don’t fully resemble human melanoma. (398) The B16F10 
cell line has greater metastatic potential than the parental B16 cell line and endogenously 
expresses Cr-1. (399) The growth speed of both the s.c. and i.v. injected B16F10 cells in 
C57Bl/6 mice only allowed us to do prophylactic vaccination. The i.v. injection of B16F10 
cells is often used as a metastasis model. (400) Nevertheless, it rather reflects the formation 
of independent pulmonary nodules, and is not a suitable model to study metastasis. While we 
observed great reduction of pulmonary foci in immunized mice, our results are only an 
indication that Cr-1 vaccination can target the metastatic process.  
Taken together, we showed that Cr-1 DNA vaccination elicits an immune response in 
C57Bl/6 mice. We further identified an immunodominant epitope and demonstrated that 
prophylactic vaccination was protective in the B16F10 murine melanoma model. 
  29 
  
Figure 8: Summary of study I 
a) Immunization of naïve C57Bl/6 mice with pmCr-1 elicits cytotoxic T cells. b) Control of i.v. and s.c. inoculated 
B16F10 cells in immunized mice. c) Vaccine induced CTLs recognize Cr-1 expressing tumor cells.  
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3.2 STUDY II 
Cripto-1 plasmid DNA vaccination targets metastasis and cancer stem cells in murine 
mammary carcinoma 
 
Background 
Based on the findings in study I we propose that Cr-1 is a suitable antigen for cancer 
vaccines. A number of studies have investigated the function of Cr-1 during embryogenesis 
and in cancer. It was shown that Cr-1 is involved in Wnt signaling, regulating EMT during 
both embryogenesis and cancer. (401, 402) Recently Cr-1 expression was associated with 
metastasis in colorectal cancer. (403) These findings support the relevance of Cr-1 within the 
metastatic process. However, it remains unclear if metastasizing cells express Cr-1 and if Cr-
1 is expressed in metastases.   
Targeting Cr-1 is also of interest because of its association with cancer stem cells.  Cr-1 is 
part of a signaling network, including Nanog, Oct-4, in stem cell maintenance. (310, 367, 
369, 404) Cr-1 expression was shown in melanoma derived cells with stem cell phenotype. 
(405) A subset of Cr-1high expressing cells within the embryogenic cancer cell line were 
reported to have a stem cell phenotype and increased capacity to form spheroids in vitro. 
(306) Further studies are required to understand the role and function of Cr-1 in cancer stem 
cells.  
Presence of EMT and cancer stem cells is a feature of aggressive, often treatment resistant, 
tumors. (1, 38) The fact that Cr-1 expression in tumors is linked to both these phenotypes, 
suggests that Cr-1 vaccination may be suitable for treatment of aggressive metastatic tumors.  
Aim of the study 
The purpose of this study is to elucidate the full potential of Cr-1 vaccination. We investigate 
if Cr-1 immunization targets and controls spontaneous tumor metastasis in mice. Further we 
explore the effect of Cr-1 vaccination on cancer stem cells.  
Results 
We chose the murine 4T1 mammary carcinoma model the effect of Cr-1 vaccination on 
metastasis and the primary tumor in parallel. The 4T1 model is a commonly used model to 
study the metastatic process because the primary tumors metastasize within 2 weeks after 
inoculation. (406) In contrast to the B16F10 cell line used in study I, Cr-1 expression was 
weak in the 4T1 cell line. Therefore, we overexpressed Cr-1 in the 4T1 cell line (4T1mCr-1). 
Naïve BALB/c mice were immunized against Cr-1 using the same protocol as in study I. 
4T1mCr-1 cells were orthotopically injected in both tumor growth and metastatic burden 
were evaluated. As reported in study I, pmCr-1 vaccination slowed down growth of the 
primary tumor but was unable to eradicate tumors. The metastatic burden in the lung was 
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strongly reduced. We decided to confirm our findings in the clinically relevant spontaneous 
mammary carcinoma model, BALB-neuT. BALB-neuT mice were vaccinated at week 10 and 
12. Mice do not exhibit palpable tumors, but show dysplasia in the mammary fat pad at the 
time point of vaccination. Despite the lack of Cr-1 expression in the primary tumors, 
metastasis to the lungs was strongly reduced in this model. Our data confirms that Cr-1 
vaccination has the ability to specifically control metastasis.  
It was left to confirm what type of immune response Cr-1 vaccination induced in BALB/c 
mice. We were unable to identify Cr-1 reactive cytotoxic T cells in pmCr-1 immunized mice. 
On the other hand, we detected Cr-1 binding antibodies in the sera of vaccinated mice. 
Antibodies have been shown to have anti-tumor activity via activation of NK cells, a process 
known as antibody-dependent cellular cytotoxicity (ADCC). (385, 407) We therefore 
hypothesized that ADCC could be a mechanism of tumor control after Cr-1 vaccination. In 
mice, only antibodies of subtype mIgG2a, and to a lesser extent, IgG2b can mediate ADCC. 
The majority of Cr-1 binding antibodies in the sera of pmCr-1 vaccinated mice belonged to 
these two subtypes. In vitro cytotoxicity assays with NK cells as effector cells in the presence 
of sera of pmCr-1 vaccinated mice confirmed our hypothesis that Cr-1 binding antibodies 
facilitate targeting of Cr-1 expressing tumor cells by NK cells.  
To evaluate the effects of Cr-1 vaccination on cancer stem cells, we confirmed the expression 
of Cr-1 in vitro cultured cancer stem cells TUBO P3. In the next step, TUBO P3 cells were 
s.c. injected in immunized mice. Cr-1 vaccination was partially successful in controlling 
CSCs in vivo. Prophylactic pmCr-1 immunization prevented tumor formation by TUBO P3 
cells in one third of the mice and reduced tumor growth in another third.  
Significance 
In this study we confirmed the findings from study I on the protective effect of Cr-1 
vaccination on tumor growth and extended the knowledge regarding the potential benefit of 
vaccination targeting metastasis and CSCs.  
A limitation of the first study was that we used a transplantable model to evaluate the effect 
of Cr-1 vaccination on tumor growth and that we used a model that is not ideally suitable to 
study metastasis. For this second study, we therefore chose the 4T1 mammary carcinoma 
model to study the effect of vaccination on metastasis in a more relevant setting. Upon 
injection of 4T1 cells into the mammary fat pad of BALB/c mice, primary tumors are 
established that metastasize to distant organs. (408) Orthotopic transplantable mouse models 
are of greater clinical relevance than transplantable models as they partially mimic the 
morphology and growth of natural tumors (409, 410). We were able to confirm that 
prophylactic Cr-1 vaccination also has a protective effect in the BALB/c strain and 
particularly decreased metastasis in the lung. A limitation to the relevance of our results is 
that we overexpressed mCr-1 in the 4T1 cell line due to very low endogenous expression. We 
therefore confirmed our findings in the BALB-neuT mammary carcinoma model. This model 
has the great advantage of being a genetically engineered spontaneously developing tumor 
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model, overexpressing rat HER2 under the MMTV promoter. (411, 412) Oncogene-induced 
hyperplasia is developed around week 4 and progresses until palpable tumors occur around 
week 20. The primary tumors also metastasize to the lungs. (413) Tumor development in the 
BALB-neuT model is similar to human breast cancer development. (414, 415) The findings 
from both models together let us conclude that Cr-1 vaccination specifically targets 
metastasis. The effect of Cr-1 vaccination also appeared to be robust, since the two animal 
models were run at independent laboratories.  
A hurdle in both study I and II was the lack of tools to detect Cr-1. Cr-1 vaccination reduced 
metastasis in the BALB-neuT mice despite Cr-1 being undetectable in the primary tumors by 
western blot. This raised the question whether Cr-1 is only expressed on a subset of cells 
undergoing EMT in the primary tumor, on circulating tumor cells or on the metastases. 
Evaluation of Cr-1 expression in the lung metastases by qPCR was a not an ideal method. We 
detected Cr-1 mRNA in the lung tissue, but were unable to confirm that the expression is in 
the metastasis. We tested several commercially available human Cr-1 antibodies, but none of 
them was suitable for detecting murine Cr-1 by either immunofluorescence or flow 
cytometry.  
In contrast to our findings in the C57Bl/6 mouse strain, vaccination was protective through 
induction of Cr-1 specific IgG2a and IgG2b antibodies in the BALB/c mouse strain. We 
suggest that this discrepancy is caused by the differences between the genetic backgrounds of 
these two mouse strains. A recent study identified that BALB/c mice are predisposed to a 
greater IgG2a response post vaccination. (416) Additional studies in mice have shown that 
tumor specific IgG2a antibodies are sufficient for tumor control in the BALB-neuT mouse 
model. (417-420) The activation of T helper cells was essential in this protection. (421) 
In addition to the validation of the humoral response, we screened for Cr-1 reactive T cells. 
Splenocytes from vaccinated mice were simulated with peptides from the overlapping peptide 
library and IFNγ production was evaluated by flow cytometry. The flow cytometry based 
screening is less common than the ELISA or ELISPOT based analysis of the IFNγ response, 
but has been done in other studies. (422, 423) We were unable to detect Cr-1 reactive T cells 
in our screening. We could speculate that Cr-1 does not contain a dominant immunogenic 
epitope or that our assay was not sensitive enough to detect low frequency clones. It remains 
to be shown if long time ex vivo stimulation of splenocytes with the Cr-1 peptide library 
could increase the frequency of Cr-1 reactive T cells allowing for detection. The detection of 
antigen specific T cells by IFNγ production is a sensitive and a commonly used method to 
detect antigen specific T cells post vaccination.  
In summary, we were able to confirm that Cr-1 DNA vaccination elicits a protective immune 
response in another mouse strain and three different mammary carcinoma models. In 
addition, we showed the potency of Cr-1 vaccination to target metastasis and CSCs.  
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Figure 9: Summary of study II  
a) Immunization of naïve BALB/c mice with pmCr-1 elicits a humoral response. b) Control of primary tumor and 
metastasis in orthotopically inoculated 4T1mCr-1 model. Control of metastasis in BALB-neuT mice, which 
spontaneously develop mammary tumors. c) Partial control of tumor formation from breast cancer stem cells. d) NK 
cell mediated ADCC of Cr-1 expressing tumor cells. 
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3.3 STUDY III 
Peripheral T cell reactivity against Cripto-1 correlates with overall survival in patients 
with advanced melanoma 
 
Background 
The expression of Cr-1 has already been shown, including, lung cancer, breast cancer and 
gastric cancer. (383) It is known that Cr-1 can be shed and it was reported to be present in the 
sera of patients with breast cancer, colon cancer, NSCLC, hepatocellular carcinoma and 
glioblastoma. (323, 347-349) However, the biological function of sCr-1 remains unclear. It 
has become evident that high levels of sCr-1 are related to poor prognosis in NSCLC and are 
a biomarker for prognosis (350, 424). The evidence for the presence of Cr-1 in melanoma is 
still limited. Cr-1 expression was described in stem cell like cells isolated from an aggressive 
melanoma cell line and a small number of primary human melanoma cell lines. (340, 405) It 
was also detected by IHC in a small study on uveal melanoma.  
In study I and II we showed that murine Cr-1 vaccination induced Cr-1 specific immune 
responses in mice. While CTL epitopes have been described for a number of tumor 
associated antigens, including cancer testis antigens NYESO-1 and MAGE-A, 
immunogenicity of human Cr-1 remains to be shown. (425, 426) 
Aim of the study 
The aim of this study is to identify the relevance and correlation with survival of soluble Cr-1 
(sCr-1) and T cell reactivity to Cr-1 in patients with advanced melanoma. 
Results 
Forty-one patients with stage IIIb, IIIc and IV melanoma, scheduled for surgical removal of a 
melanoma lesion, were included in our patient cohort. Two blood samples were collected; 
one before and one after surgery, with a median time of 34 days between the blood draws.  
Based on previous reports, we evaluated Cr-1 protein concentrations in the serum, both pre- 
and post-surgery. sCr-1 was present in more than 80% of stage IIIc and IV patients, but only 
in 50% of stage IIIb patients before surgery. Surgery did not influence the levels of sCr-1 
found in the patient sera. However, high levels of circulating Cr-1 protein (>587.4 pg/ml) 
after surgery correlated with worse survival. 
We next aimed to identify Cr-1 reactive T cells in the patient peripheral blood PBMCs. 
PBMCs were stimulated for 12 days with the human Cr-1 15-mer peptide library, based on 
the protocol to detect tumor reactive T cells in PBMCs established by Weide et al. (427) 
Using this assay, Cr-1 reactive CD4+ and CD8+ T cells were detected in 60% of the patients 
before surgery, mainly in stage IIIb patients. The presence of Cr-1 reactive CD4+ and CD8+ T 
cells in circulation correlated with better OS and longer PFS in this cohort. Surgical removal 
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of melanoma lesions increased T cell reactivity to Cr-1, in particularly that of CD8+ T cells. T 
cell reactivity post-surgery was not correlated with prognosis.  
Deeper analysis of the cytokine profile of Cr-1 reactive CD4+ and CD8+ T cells revealed that 
mainly pro-inflammatory cytokines (IFNγ, TNFα, IL-2) were produced in response to Cr-1 
peptide stimulation. In line with the increase in total T cell reactivity, we observed an 
increase in multi-cytokine responses in patients after surgery. Interestingly, specific cytokine 
responses in Cr-1 reactive CD4+ T cells were more predictive for OS than those in CD8+ T 
cells.  
Significance 
In this study, we explored the intrinsic immunity against Cr-1 in melanoma patients to 
potentially identify sCr-1 or T cell reactivity to Cr-1 as a novel biomarker in advanced 
melanoma.  
In line with studies on other cancer types, we were able to confirm the presence of sCr-1 in 
the sera of advanced melanoma patients. (323, 347-349) Cripto-1 expression has been 
described before in samples from early and late stage melanoma. (340) However, we did not 
yet confirm expression of Cr-1 in the tumor samples from our patient cohort. 
High concentrations of sCr-1 in post-surgical patient sera were associated with shorter 
survival, although we did not observe a significant decrease of sCr-1 protein in the serum of 
patients after surgery. One possible explanation could be that serum Cr-1 levels did not yet 
normalize within our follow-up period. Studies on other serum biomarkers IGF-1, CEA and 
CA19-9 have found that normalization occurs between one and three months after surgical 
removal of the tumor. (428, 429) A drawback of our serum analysis is that we did not includ 
serum from healthy donors yet. The detected serum levels in our patient cohort and the 
mathematically determined cut-off point for low and high Cr-1 levels are in line with the 
findings in other studies. (323, 347-349)  However, inclusion of sera from healthy donors will 
deepen our knowledge on the biological and clinical relevance of our findings.  
For the first time, we were able to Cr-1 specific T cells in cancer patients. Circulating T cells 
that are reactive to known melanoma antigens and neoantigens have previously been 
identified in melanoma patients. (430-432) Using a long-term T cell stimulation assay, we 
detected Cr-1 reactive T cells in the peripheral blood of patients with advanced melanoma. 
We used a human Cr-1 overlapping peptide library to detect Cr-1 reactive T cells, which 
allowed us to evaluate responses in all patients, independent of their HLA subtype. However, 
this brings a disadvantage, since 15 amino acid long peptides do not optimally bind to MHC 
class I. We followed and established 12-day stimulation protocol. (427) Due to low amounts 
of frozen PBMCs, we stimulated our T cell cultures with peptides alone, while a more 
optimal setting would have been to include peptide-loaded autologous PBMC. This has 
shown to significantly increase the frequency of peptide reactive T cells. (433) Because of the 
long pre-stimulation and the low frequency of cytokine producing T cells after re-stimulation 
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with the peptide library, we decided against a quantitative analysis. This is a drawback of the 
study, as we cannot correlate response intensity to outcome. However, there are indications 
that T cell reactivity is associated with longer survival. In order to confirm that Cr-1 reactive 
T cells were primed by tumor derived antigens and are not an artifact, Cr-1 T cell reactivity 
should be evaluated in healthy donor PBMC.  
In summary we confirmed the presence of soluble Cr-1 in the sera of patients with advanced 
melanoma and its correlation with survival. Surgical removal of tumor mass increased the 
reactivity of circulating CD8+ and CD4+ T cells to Cr-1. Our data suggest that T cell cytokine 
responses to Cr-1 correlate with survival as well. 
 
 
Figure 10: Summary of study III  
a) Two blood samples were collected from all patients, one before and one after surgical removal of melanoma lesion. 
Soluble Cr-1 in serum was measured by ELISA. b) PBMCs are stimulated with Cr-1 peptides for 12 days prior to re-
stimulation and in vitro detection of Cr-1 reactive T cells.  
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4 CONCLUSION 
 
With the clinical approval of the first checkpoint inhibitor in melanoma treatment in 2011 and 
the Nobel Prize award in 2018 for the discovery of using the inhibition of immune 
checkpoints in cancer therapy, immunotherapy got into the focus of scientist, clinicians, and 
the general public.  
Increasingly more research is being conducted within the field of tumor immunology, 
broadening our knowledge and deepening our understanding for the interaction between the 
tumor and the immune system. This valuable knowledge enables us to develop novel 
immunotherapeutic strategies, and even more importantly, allows us to identify the right 
patient groups. Cancer vaccines can be of great benefit to patients who lack tumor specific T 
cells and will not response to the blockade of the PD-1/PD-L1 axis. Vaccination with TAAs 
can increase the diversity of tumor reactive T cells and enhance reactivity against self-
antigens.  
In this thesis, we have demonstrated that Cr-1 is a target for cancer immunotherapy. In study 
I and II we showed that a vaccine based treatment approach elicited Cr-1 specific immune 
responses in two mouse strains. Moreover, it was protective in murine melanoma and murine 
mammary carcinoma models. We further showed that Cr-1 vaccination specifically reduced 
metastasis and partially prevented tumor formation from CSCs. In study III we investigated 
the potential of Cr-1 as a biomarker in advanced melanoma. We found that both low levels of 
sCr-1 in the sera and the presence of circulating Cr-1 reactive T cells correlated with better 
survival in our cohort. Altogether, we identified Cr-1 as a potential biomarker and interesting 
target for cancer immunotherapy.  
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